

SAHA Patient: IV vs ORAL (200 mg/dose)




FIG. 1

**Protocol 01-021 (ORAL SAHA) ARM A: SOLID
TUMOR PATIENTS Cohort I (200 mg/dose)**




FIG. 2

SAHA Patients: ORAL /Cohort I (200 mg/dose)




FIG. 3

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort I (200 mg/dose)






FIG. 4

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)
7-OS-400 8-OS-400



12/19/01

9-OS-400



12/27/01

FIG. 5

SAHA Patients: ORAL/Cohort II (400 mg/dose)




FIG. 6

Pr tocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)




FIG. 7

SAHA Patients: ORAL/Cohort II (400 mg/dose)





FIG. 8

Oral 200 mg vs. 400 mg (Fasting)

Oral dose on Cycle 1 Day 8




Figure 9A

Oral 200 mg vs. 400 mg (no-fasting)

Oral Dose on Cycle 1 Day 9




Figure 9B

IV 200 mg vs. 400 mg

IV Dose on Cycle 1 Day 1





Figure 9C


Apparent Half-life of the Oral Dose



3/4/2003

Figure 10

AUC of the Oral Dose



■ = 200 mg group (n=3-5); □ = 400 mg group (n=5-10)

3/4/2003

Figure 11

Bioavailability





Figure 12



A




B


Figure 13

CONFIDENTIAL

ATON
PHARMA



A



B

Figure 14

CONFIDENTIAL

ATON
PHARMA



A

B

Figure 15

CONFIDENTIAL

ATON
PHARMA

Pre-Therapy

2 months Post SAHA






Figure 16

CONFIDENTIAL

ATON
P H A R M A